Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Factors that aid survival of prostate cancer cells in the presence of the various categories of cytotoxic cytokines present in tumors in vivo are largely unknown. Osteoprotegerin (OPG) is a decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that inhibits TRAIL-induced...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Holen, I, Croucher, P, Hamdy, F, Eaton, C
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2002

Gelijkaardige items

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
door: Eaton, C, et al.
Gepubliceerd in: (2004)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
door: Eaton, C, et al.
Gepubliceerd in: (2004)

OPG is a survival factor for breast- and prostate cancer cells in vitro
door: Holen, I, et al.
Gepubliceerd in: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
door: Holen, I, et al.
Gepubliceerd in: (2002)

Role of osteoprotegerin (OPG) in cancer.
door: Holen, I, et al.
Gepubliceerd in: (2006)

The role of osteoprotegerin in breast and prostate cancer
door: Holen, I, et al.
Gepubliceerd in: (2002)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
door: Holen Ingunn, et al.
Gepubliceerd in: (2009-07-01)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
door: Shipman, C, et al.
Gepubliceerd in: (2002)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
door: Lili Zhang, et al.
Gepubliceerd in: (2016-11-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
door: Shipman, C, et al.
Gepubliceerd in: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
door: Shipman, C, et al.
Gepubliceerd in: (2000)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
door: Gamal B Mohamed, et al.
Gepubliceerd in: (2011-01-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
door: Waterman, E, et al.
Gepubliceerd in: (2007)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
door: Miles, L, et al.
Gepubliceerd in: (2004)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
door: Croucher, P, et al.
Gepubliceerd in: (2000)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
door: Noura N. Alraouji, et al.
Gepubliceerd in: (2024-08-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
door: Riham Eid, et al.
Gepubliceerd in: (2023-06-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
door: Shipman, C, et al.
Gepubliceerd in: (2003)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
door: Siamak Kazemi-Sufi, et al.
Gepubliceerd in: (2024-09-01)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
door: Nyambo, R, et al.
Gepubliceerd in: (2004)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
door: Nyambo, R, et al.
Gepubliceerd in: (2004)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
door: Chan Kai-Ming, et al.
Gepubliceerd in: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
door: Syed Muhammad Muneeb Akhtar, et al.
Gepubliceerd in: (2024-07-01)

Osteoprotegerin and the development of myeloma bone disease
door: Croucher, P, et al.
Gepubliceerd in: (2004)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
door: Yao Jing, et al.
Gepubliceerd in: (2011-03-01)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
door: Saba Tariq, et al.
Gepubliceerd in: (2022-02-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
door: Yosra Azizpour, et al.
Gepubliceerd in: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
door: Yosra Azizpour, et al.
Gepubliceerd in: (2020-01-01)

The survival effect of prolactin on PC3 prostate cancer cells.
door: Ruffion, A, et al.
Gepubliceerd in: (2003)

Involvement of FXR in the OPG/RANKL pathway of breast and prostate cancer cells
door: Lara Absil, et al.
Gepubliceerd in: (2021-04-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
door: Indra Wijaya, et al.
Gepubliceerd in: (2024-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
door: Croucher, P, et al.
Gepubliceerd in: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
door: Croucher, P, et al.
Gepubliceerd in: (2001)

Determinant Factors and Added Value of Osteoprotegerin (OPG) to Detect Carotid Intima-Media Thickness (CIMT) in Type 2 Diabetes Mellitus Patient
door: Shirly Elisa Tedjasaputra, et al.
Gepubliceerd in: (2018-06-01)

Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
door: Salvador Atilano-Miguel, et al.
Gepubliceerd in: (2022-01-01)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
door: Lane Denis, et al.
Gepubliceerd in: (2012-11-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
door: Martin Widschwendter, et al.
Gepubliceerd in: (2015-10-01)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
door: Cross, N, et al.
Gepubliceerd in: (2008)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.
door: Cross, N, et al.
Gepubliceerd in: (2008)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
door: Vanderkerken, K, et al.
Gepubliceerd in: (2003)